Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$241.6 million.

  • NewAmsterdam Pharma Co N.V's Income towards Parent Company fell 332.54% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.54% down from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Income towards Parent Company of -$241.6 million as of FY2024, which was down 36.54% from -$176.9 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Income towards Parent Company high stood at -$6.6 million for FY2020, and its period low was -$241.6 million during FY2024.
  • Moreover, its 3-year median value for Income towards Parent Company was -$176.9 million (2023), whereas its average is -$166.1 million.
  • Data for NewAmsterdam Pharma Co N.V's Income towards Parent Company shows a maximum YoY slumped of 415.60% (in 2021) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Income towards Parent Company (Yearly) stood at -$6.6 million in 2020, then tumbled by 415.60% to -$33.8 million in 2021, then plummeted by 135.29% to -$79.6 million in 2022, then tumbled by 122.19% to -$176.9 million in 2023, then tumbled by 36.54% to -$241.6 million in 2024.